GlassScriptPhysician profile
Angela Armstrong
NPI 1437891413
$2,398.26
in general payments reported to CMS, 2019-2025
18 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $336 · 2023: $260 · 2024: $567 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $333.29 | 2022-2025 | Azstarys |
| Abbvie INC. | $309.59 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $277.22 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $249.00 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $214.27 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $191.70 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $145.51 | 2022-2025 | Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $132.23 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $107.40 | 2022-2025 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $101.16 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $84.55 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $83.61 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $52.29 | 2024 | |
| Bausch Health US, LLC | $37.30 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.78 | 2025 | Caplyta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $20.88 | 2025 | Trintellix |
| Tris Pharma INC | $18.47 | 2025 | Onyda Xr |
| Idorsia Pharmaceuticals US INC | $15.01 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.